Management of buprenorphine/naloxone therapy in substances abuse consumers in prison: efficacy and safety
Il management della terapia con buprenorfina/naloxone nei consumatori di sostanze in carcere: efficacia e sicurezza
The use of agonist therapy in prison is not widespread in Italy or in the rest of the world. This causes a strong limitation in access to care for inmates, but above all causes serious negative consequences on public health, due to the lack of treatment of a population otherwise difficult to reach. This population, if left untreated, presents greater risks, when discharged from jail, of relapse in use, of infectious diseases occurrence and of death by overdose. Inappropriate treatment also causes a greater difficulty in the management of the inmate: several behavioral disorders, such as self-harm, self and hetero-aggression, and suicide attempts, can be prevented through an appropriate use of agonist therapy. One of the primary objectives in the management of illicit substance users is the increase in the proper use of agonistic treatments, in their duration and dosage and the improvement of their safety profile through the prevention of episodes of misuse and/or diversion. This can be achieved through the use of partial agonist drugs and abuse-deterrent formulations such as buprenorphine/naloxone (Pharmacology)
Copyright (c) 2018 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors contributing to AboutOpen agree to publish their articles under the Creative Commons NonCommercial 4.0 International License (CC BY-NC 4.0), which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.